ESH Video

International Conference on AML "Molecular and translational" - Advances in the Biology and Treatment

International Conference on AML "Molecular and translational" - Advances in the Biology and Treatment
September 10 - September 12, 2015 - Budapest, Hungary
Chairs : Hartmut Döhner, Bob Löwenberg, Martin Tallman


International Conference on
ACUTE MYELOID LEUKEMIA: “Molecular and translational” –
Advances in the Biology and Treatment

September 10-12, 2015 – Budapest, Hungary
Chairs: B. Löwenberg, H. Döhner, M. Tallman




Molecular techniques are creating novel insights into the biology and therapeutic perspectives of AML. Molecular diagnosis allows us to distinguish distinct disease entities and to identify patients with different disease behavior and prognosis. Genomic and epigenetic studies have revealed entirely novel insights into the biology of AML, expanded the genomic landscape in unprecedented depth and discovered functional clues of dysregulation. Thus, these studies have profoundly enhanced our understanding of the pathobiology of the disease and identified major pathways of malignant transformation. These insights also furnish keys to the development of novel specifically acting therapeutic drugs and provide the opportunity to develop more sophisticated risk-adjusted therapeutic approaches.


This Conference on ACUTE MYELOID LEUKEMIA intends to promote informal interaction and ample discussion between scientists and clinicians working in the field. Scientific presentations by international leaders will provide the current status and a perspective of these exciting developments. In separate sessions results from both basic and clinical research will be presented. The target audience will comprise besides key opinion leader scientists, PhD students, basic scientists, physician-scientists, as well as clinicians with an interest in the field.


The program will include:

  • Plenary Sessions
  • Discussions and debates
  • Simultaneous Meet the Expert sessionsPoster sessions


This meeting will be valuable or you if you are looking for:

  • A cutting-edge scientific program – from basic science to clinical and therapeutic applications and perspectives
  • Multiple opportunities for scientific interaction with an international faculty of distinguished experts
  • An emphasis on critical discussion



Learning Objectives

  • Understand the pathobiology of leukaemia and its development with respect to alterations in hematopoietic stem cells, their microenvironment and altered signal transduction pathways
  • Acquire insight into the possible mechanisms of preleukaemic disorders and genomic instability that predispose to leukemogenesis and predispose also to disease progression.
  • Understand about the characterisation of a leukemia stem cell and its relationship to disease development and phenotype
  • Learn about the pathobiologic importance of epigenetic dysregulation in the development of acute myeloid leukemia (eg, methylation, microRNA) and its clinical impact
  • Evaluate the merits and relevance of molecular diagnostics and minimal residual disease assessment in relation to various management decisions
  • Gain insight into novel therapeutics of acute myeloid leukemia, including knowledge about their mechanisms of action, the current developmental status of various targeted drugs and their promises for future clinical application.


AML Programme 1808 2015 1 AML Programme 1808 2015 2 AML Programme 1808 2015 3 AML Programme 1808 2015 4 AML Programme 1808 2015 5

Abstract submission

The deadline to submit an abstract has been reached. 




ESH local conference secretariat
c/o Forum d’Ideias, Lda.
Rua da Juventude Azeitonense, Lote 137B
2925-588 V.N. Azeitão / Portugal
Tel: +351 21 218 93 93
Fax: +351 21 218 93 92



Marriott Budapest
Apáczai Csere János utca 4, 
1052 Hungary

Corporate partners

With the support of

Major Conference Partner

ESH Platinum Institutional Partner



Level 1 Conference Partner


 Level 2 Conference Partners






Supporting Partners






Educational Grants